The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | The clinical use of tyrosine kinase inhibitors in EGFR-mutant NSCLC
Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, evaluates the use of tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). Studies such as RADIANT (NCT00373425) support TKIs for use in resectable cases but have not demonstrated changes in overall survival. ADAURA (NCT02511106) assessed the use of osimertinib and due to significant improvements in disease-free survival, is currently the only TKI study that has resulted in a clinical practice change. The highly anticipated overall survival results also support osimertinib use. This is significant considering the drug’s unique CNS penetration across the blood-brain barrier as demonstrated in the FLAURA study (NCT02296125) and strong toxicities which currently prevent its use an adjuvant therapy in the first-line setting, despite its efficacy. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
